These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1725797)

  • 1. Nitrendipine and metabolic balance.
    Ferrara LA; Marotta T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 5():S19-21. PubMed ID: 1725797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic neutrality in nitrendipine therapy.
    Mancini M; Marotta T; Ferrara LA
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S30-3. PubMed ID: 1723452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of exogenous triglyceride removal following calcium channel blockade.
    Marotta T; Ferrara LA; Pasanisi F; Rubba P; Iovine C; Mancini M
    Artery; 1989; 16(6):312-26. PubMed ID: 2679494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does long-term blood pressure reduction in patients with essential hypertension improve concomitant metabolic disorders?].
    Hauner H; Meissner C
    Med Klin (Munich); 1994 Aug; 89(8):403-9. PubMed ID: 7968872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance and hypertension in postmenopausal women.
    Feldstein CA; Akopian M; Renauld A; Olivieri AO; Cauterucci S; Garrido D
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S145-50. PubMed ID: 11986914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alteration of blood glucose, insulin and lipid in the offsprings of patients with essential hypertension].
    Yang T; Sun M; Zhou H; Xie X
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):37-40. PubMed ID: 11938735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension.
    Fuh MM; Shieh SM; Wu DA; Chen YD; Reaven GM
    Arch Intern Med; 1987 Jun; 147(6):1035-8. PubMed ID: 3296980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of fuel metabolism in the polycystic ovary syndrome.
    Wortsman J; Soler NG
    Obstet Gynecol; 1982 Sep; 60(3):342-5. PubMed ID: 6214733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension.
    Malminiemi K; Lahtela JT; Huupponen R
    Int J Clin Pharmacol Ther; 1995 Mar; 33(3):156-63. PubMed ID: 7599914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic risk factors in white coat hypertensives.
    Marchesi E; Perani G; Falaschi F; Negro C; Catalano O; Ravetta V; Finardi G
    J Hum Hypertens; 1994 Jul; 8(7):475-9. PubMed ID: 7932508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of pindolol on plasma lipids, apoproteins A, blood glucose, and serum insulin levels.
    Lehtonen A
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):269-72. PubMed ID: 6430812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metabolic control of the serum lipid and lipoprotein levels on insulin-dependent diabetes mellitus.
    Romics L; Karádi I; Rozenberczki M; Kammerer L
    Acta Med Acad Sci Hung; 1982; 39(3-4):117-23. PubMed ID: 6764327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrendipine does not impair long-term glucose control in hypertensive noninsulin-dependent diabetic patients.
    Giuntoli F; Galeone F; Gabbani S; Natali A; Brunelleschi G; Saba P; Stampino CG
    Clin Ther; 1991; 13(2):216-23. PubMed ID: 1907527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The significance of insulin resistance and hyperlipidemia in microvascular angina (syndrome X)].
    Langes K; Volk C; Schneider MA; Koschyk DH; Rinninger F; Nienaber CA
    Z Kardiol; 1995 Mar; 84(3):180-9. PubMed ID: 7732710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do beta-blockers alter lipids and what are the consequences?
    Holtzman E; Rosenthal T; Goldbourt U; Segal P
    J Cardiovasc Pharmacol; 1987; 10 Suppl 2():S86-92; discussion S93. PubMed ID: 2481177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.